We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
ADVANCES IN THE METABOLOMIC SIGNATURES IN BONE OSTEOPOROSIS AND CANCER.
- Authors
Ganesan, Raja; Prabhakaran, Vasantha-Srinivasan; Balasubramanian, Arumugam
- Abstract
Osteoporosis is a highly prevalent disorder characterized by low bone mineral density (BMD) and increased risk of fracture, termed osteoporotic fracture. Cancer is a major risk factor for bone loss and fracture. Metabolomic technologies have evolved rapidly, contributing the basic metabolic activity of bone diseases in body. The identification of the metabolic determinant of osteoporosis and bone mass disorder has not yet been summarized. Metabolic signalling activity of bone tissue regeneration is crucial for mesenchymal stem cells (MSCs) differentiation, scaffolds, bone remodelling and metabolism. The bone cancer osteosarcoma-associated bone loss is the result of multiple inter-related factors. Numerous discovered biomarker metabolites merit functional follow-up studies to elucidate their role in bone metabolism. The knowledge gained from the cancer-specific metabolome investigations helps to redefine bone disease, find new medication targets for skeletal disorders and identify biomarkers that are predictive of bone disease in body. Based on their safety, effectiveness and cost performance, researchers are becoming more and more interested in creating novel treatments for osteoporosis employing MSCsbased metabolites therapy in tumour microenvironment. The personalized management of BMD, osteoporosis and osteosarcoma-based metabolomics profiling may benefit from advancements in both diagnostic and therapeutic targets.
- Subjects
BONE density; BONE regeneration; BONE cancer; METABOLOMICS; METABOLIC bone disorders; MESENCHYMAL stem cells; BONE diseases
- Publication
Veterinaria, 2022, Vol 71, Issue 3, p301
- ISSN
0372-6827
- Publication type
Article
- DOI
10.51607/22331360.2022.71.3.301